GlaxoSmithKline Pharmaceuticals Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for FY26 to BSE Limited and the National Stock Exchange of India Limited. The filing, made on June 5, 2026, details the company's performance on environmental, social, and governance parameters. The report, which forms part of the Annual Report, has undergone reasonable assurance by Bureau Veritas India Pvt. Ltd.

The company reported a Corporate Social Responsibility (CSR) expenditure of ₹1,859.48 Lakhs for the financial year. This spending represents 2% of the average net profit from the previous three financial years. The initiatives reached over 60,000 beneficiaries, focusing on healthcare infrastructure and quality education for underprivileged communities.

Environmental Performance

GlaxoSmithKline Pharmaceuticals achieved a reduction in its environmental footprint during the year. Total greenhouse gas (GHG) emissions decreased from 10,422 tonnes of CO2 equivalent (tCO2e) in FY 2024-25 to 9,346 tCO2e in FY 2025-26, a reduction of 10.32%. The Nashik manufacturing site generated 495.61 MT of direct Scope 1 CO2 emissions, while Scope 2 emissions were nil due to full coverage by Renewable Energy Certificates.

Water consumption also declined significantly. The company reported total water consumption of 66,608 kilolitres (kL) in FY 2025-26, compared to 76,714 kL in the previous year, marking a 13.2% reduction. The Nashik plant successfully achieved Zero Liquid Discharge (ZLD) by recycling 100% of treated process effluent.

Operational and Employee Metrics

The company’s total workforce comprised 1,507 employees and 1,623 workers as of the end of the financial year. Women constituted 16.79% of the total employees and 10.47% of the total workers. The Board of Directors included 7 members, with female representation at 29%. Key Management Personnel had a female representation of 43%.

Financial and Governance Details

The company recorded a turnover of ₹3,79,020.27 Lakhs and a net worth of ₹2,24,117.21 Lakhs. Paid-up capital stood at ₹16,940.60 Lakhs. The report confirmed that there were no fines or penalties imposed by regulators during the year, and no instances of anti-competitive conduct were identified.

GlaxoSmithKline Pharmaceuticals Limited has announced the resignation of Dr. Simrat Sohal from the position of Compliance Officer and Senior Management Personnel. The resignation is effective from the close of business hours on August 5, 2026, as she intends to pursue opportunities outside the organization. Consequently, she will cease to be a Senior Management Personnel of the company effective the said date.

The company informed the stock exchanges regarding this change in senior managerial personnel in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was also made in accordance with SEBI Circular Nos. CIR/CFD/CMD/412015 dated September 9, 2015 and Exchange Circular List/Comp/14/2018-19 dated June 20, 2018.

Resignation Details

The filing provided specific particulars regarding the cessation of Dr. Sohal's role within the company. The reason for the change was cited as a resignation to pursue external opportunities.

Dr. Simrat Sohal had submitted her resignation notice on May 19, 2026, confirming her final working day as August 5, 2026. She expressed her commitment to ensuring a smooth transition and completing all handover responsibilities during her notice period. The acceptance of the resignation was confirmed by the company management.